Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 Terminated
55 enrolled
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
BIS-Program
Phase 2 Terminated
33 enrolled
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Phase 2 Terminated
11 enrolled 13 charts
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Phase 1/2 Terminated
2 enrolled 6 charts
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Phase 1 Terminated
2 enrolled
Decrescendo
Phase 2 Terminated
139 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Phase 2 Terminated
7 enrolled 10 charts
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Phase 2 Terminated
33 enrolled
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Phase 2 Terminated
2 enrolled 7 charts
PREDIXIIHER2
Phase 2 Terminated
6 enrolled
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Phase 2 Terminated
32 enrolled 15 charts
STEFNE
Phase 1/2 Terminated
8 enrolled 1 chart
Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
Phase 1 Terminated
1 enrolled
Neohttp
Phase 1/2 Terminated
4 enrolled 1 chart
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Phase 1 Terminated
6 enrolled
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Phase 2 Terminated
4 enrolled 5 charts
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Phase 2 Terminated
1 enrolled 4 charts
A Study of Pertuzumab in Participants With Prostate Cancer
Phase 2 Terminated
68 enrolled 18 charts